🇺🇸 FDA

Intelligence · Clinical Pipeline

Chongqing Precision Biotech Pipeline

All ClinicalTrials.gov programs at Chongqing Precision Biotech — phase, modality, and trial IDs.

Programs
34

Quick answer

Chongqing Precision Biotech has 34 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. 10 mg PRAX-114

    Chongqing Precision Biotech Co., Ltd

    Major Depressive Disorder

    phase 2 small molecule completed

    1 trial

  2. 10 mg PRAX-114, 20 mg PRAX-114, and Placebo

    Chongqing Precision Biotech Co., Ltd

    Essential Tremor

    phase 2 small molecule terminated

    1 trial

  3. 100 mg PRAX-944

    Chongqing Precision Biotech Co., Ltd

    Essential Tremor

    phase 2 small molecule completed

    1 trial

  4. 30mg PRAX-628

    Chongqing Precision Biotech Co., Ltd

    Focal Onset Seizure

    phase 2 small molecule active

    1 trial

  5. 60 mg PRAX-114 or 40 mg PRAX-114

    Chongqing Precision Biotech Co., Ltd

    Post-traumatic Stress Disorder

    phase 2 small molecule terminated

    1 trial

  6. Atorvastatin Oral Tablet

    Chongqing Precision Biotech Co., Ltd

    Mild Cognitive Impairment

    phase 2 small molecule active

    1 trial

  7. BCMA CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Multiple Myeloma

    phase 2 mab active

    2 trials

  8. BCMA targeted prime CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Multiple Myeloma

    phase 2 mab active

    1 trial

  9. CD123 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Leukemia

    phase 2 mab active

    2 trials

  10. CD123 targeted CAR-NK cells

    Chongqing Precision Biotech Co., Ltd

    Acute Myeloid Leukemia

    phase 2 mab active

    1 trial

  11. CD19 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Leukemia

    phase 2 mab active

    2 trials

  12. CD19 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Autoimmune Diseases

    phase 2 mab active

    1 trial

  13. CD19 and CD22 targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Leukemia, B-cell

    phase 2 mab active

    2 trials

  14. CD19 and CD22 targeted prime CAR- T cells

    Chongqing Precision Biotech Co., Ltd

    B Cell Lymphoma

    phase 2 mab active

    1 trial

  15. CD19 and CD22 targeted prime CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    B-ALL

    phase 2 mab active

    1 trial

  16. CEA CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Solid Tumor

    phase 2 mab active

    1 trial

  17. CEA-targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Gastric Cancer

    phase 2 mab active

    3 trials

  18. Gemcitabine

    Chongqing Precision Biotech Co., Ltd

    Pancreatic Cancer, Adult

    phase 2 small molecule terminated

    1 trial

  19. Melphalan flufenamide (Melflufen)

    Chongqing Precision Biotech Co., Ltd

    Multiple Myeloma

    phase 2 small molecule completed

    1 trial

  20. NEO-201 in combination with pembrolizumab

    Chongqing Precision Biotech Co., Ltd

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  21. NPC-1C/NEO-102

    Chongqing Precision Biotech Co., Ltd

    Metastatic Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  22. NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy)

    Chongqing Precision Biotech Co., Ltd

    Soft Tissue Sarcoma

    phase 2 mab active

    1 trial

  23. OPM-101

    Chongqing Precision Biotech Co., Ltd

    Advanced Melanoma

    phase 2 small molecule active

    1 trial

  24. PBCAR20A

    Chongqing Precision Biotech Co., Ltd

    Non-Hodgkin's Lymphoma, Relapsed

    phase 2 gene therapy completed

    1 trial

  25. PBGENE-DMD (IV)

    Chongqing Precision Biotech Co., Ltd

    Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD

    phase 2 mab active

    1 trial

  26. PCN-101

    Chongqing Precision Biotech Co., Ltd

    Treatment Resistant Depression

    phase 2 small molecule completed

    1 trial

  27. PDI-192

    Chongqing Precision Biotech Co., Ltd

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  28. PDI-320

    Chongqing Precision Biotech Co., Ltd

    Rosacea

    phase 2 small molecule active

    1 trial

  29. PRAX-222 - Initial Dose

    Chongqing Precision Biotech Co., Ltd

    SCN2A-DEE

    phase 2 small molecule active

    1 trial

  30. PRAX-628

    Chongqing Precision Biotech Co., Ltd

    Focal onset seizures or primary generalized tonic-clonic seizures

    phase 2 small molecule active

    1 trial

  31. Part A: 20 and 40 mg PRAX-944

    Chongqing Precision Biotech Co., Ltd

    Essential Tremor

    phase 2 small molecule completed

    1 trial

  32. delolimogene mupadenorepvec

    Chongqing Precision Biotech Co., Ltd

    Malignant Melanoma

    phase 2 gene therapy completed

    1 trial

  33. donor-derived NK cell infusion

    Chongqing Precision Biotech Co., Ltd

    Non-small Cell Lung Cancer

    phase 2 mab active

    1 trial

  34. pCAR-19B cells

    Chongqing Precision Biotech Co., Ltd

    Acute Lymphoblastic Leukemia

    phase 2 mab active

    2 trials

Frequently asked questions

How many pipeline programs does Chongqing Precision Biotech have?

34 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.